@JoshuaDWallach @akapczynski @gregggonsalves @Yale_CRIT @JohnArnoldFndtn @US_FDA @JeremyPuthumana @cmrherder @AudreyDZhang @jasonlschwartz @califf001 @alex_egilman @CMSGov More than $29B on 104 drugs and biologics that were found to lack sufficient evidenc
RT @JournalGIM: From 2011-2016, @CMSGov and its beneficiaries spent $29.2B on 104 drugs & biologics that lacked sufficient evidence of effi…
Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies https://t.co/OnSCIocNgy
RT @PDX_Tom: No surprise...we have serious problem of regulatory capture at @US_FDA @VPrasadMDMPH @eturnermd1 @adamcifu @METRICStanford…
RT @JoshuaDWallach: “we’re not using resources in the most efficient, cost effective manner.....we spend too much on drugs" - @alex_egilman…
“we’re not using resources in the most efficient, cost effective manner.....we spend too much on drugs" - @alex_egilman in a great piece by @pharmalot https://t.co/v4BI22Yxn7 via @statnews @jsross119 @gregggonsalves @YaleMed @YaleSPH @Yale_CRIT https:
RT @JournalGIM: From 2011-2016, @CMSGov and its beneficiaries spent $29.2B on 104 drugs & biologics that lacked sufficient evidence of effi…
RT @jsross119: Today in @JournalGIM, we report our @Yale_CRIT study led by @alex_egilman, funded by @JohnArnoldFndtn, estimating how much…
RT @PDX_Tom: No surprise...we have serious problem of regulatory capture at @US_FDA @VPrasadMDMPH @eturnermd1 @adamcifu @METRICStanford…
RT @JournalGIM: From 2011-2016, @CMSGov and its beneficiaries spent $29.2B on 104 drugs & biologics that lacked sufficient evidence of effi…
RT @JournalGIM: From 2011-2016, @CMSGov and its beneficiaries spent $29.2B on 104 drugs & biologics that lacked sufficient evidence of effi…
RT @JournalGIM: From 2011-2016, @CMSGov and its beneficiaries spent $29.2B on 104 drugs & biologics that lacked sufficient evidence of effi…
Thank you @CADTH_ACMTS for the great work your teams do. @CMSGov seems to have wasted $29B on drugs with poor evidence or low value.
This of how much #SDoH might have been impacted with that $29 billion… 🤬
RT @JournalGIM: From 2011-2016, @CMSGov and its beneficiaries spent $29.2B on 104 drugs & biologics that lacked sufficient evidence of effi…
From 2011-2016, @CMSGov and its beneficiaries spent $29.2B on 104 drugs & biologics that lacked sufficient evidence of efficacy and/or value to receive coverage by Australia, Canada, and England HTA agencies @JournalGIM @jsross119 @alex_egilman https:/
"Medicare and its beneficiaries spent $29.2 billion on 104 unique drugs and biologics that were found to lack sufficient evidence of efficacy and/or value" by national #HTA agencies - @jsross119 et al https://t.co/mNfcyHTr1s @DavidP4AD @rkessler05 @iqwig
RT @YaleSPH: Read more about the study by Yale CRIT’s @alex_egilman, YSPH’s @JoshuaDWallach and @Gregggonsalves, and YSM’s @jsross119 in @J…
RT @jsross119: Today in @JournalGIM, we report our @Yale_CRIT study led by @alex_egilman, funded by @JohnArnoldFndtn, estimating how much…
RT @JournalGIM: JGIM shareable article link: https://t.co/kdZdaqJQdE https://t.co/e622Emj9DK
JGIM shareable article link: https://t.co/kdZdaqJQdE
RT @YaleSPH: Read more about the study by Yale CRIT’s @alex_egilman, YSPH’s @JoshuaDWallach and @Gregggonsalves, and YSM’s @jsross119 in @J…
RT @YaleSPH: Read more about the study by Yale CRIT’s @alex_egilman, YSPH’s @JoshuaDWallach and @Gregggonsalves, and YSM’s @jsross119 in @J…
RT @YaleSPH: Read more about the study by Yale CRIT’s @alex_egilman, YSPH’s @JoshuaDWallach and @Gregggonsalves, and YSM’s @jsross119 in @J…
Read more about the study by Yale CRIT’s @alex_egilman, YSPH’s @JoshuaDWallach and @Gregggonsalves, and YSM’s @jsross119 in @JournalGIM at https://t.co/ajPN33BOlo. @Yale_CRIT @YaleMed @YaleDeptEHS @JohnArnoldFndtn @CMSGov @icer_review https://t.co/1HFAiLd3
RT @JournalGIM: Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencie…
RT @JournalGIM: from JGIM author @alex_egilman Article link: https://t.co/YD9aUaTUKo https://t.co/eRQIR37LwT
RT @jsross119: Today in @JournalGIM, we report our @Yale_CRIT study led by @alex_egilman, funded by @JohnArnoldFndtn, estimating how much…
from JGIM author @alex_egilman Article link: https://t.co/YD9aUaTUKo
Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies https://t.co/DKiVdBeoSm
RT @jsross119: Today in @JournalGIM, we report our @Yale_CRIT study led by @alex_egilman, funded by @JohnArnoldFndtn, estimating how much…
RT @jsross119: Today in @JournalGIM, we report our @Yale_CRIT study led by @alex_egilman, funded by @JohnArnoldFndtn, estimating how much…
Great to collaborate with @alex_egilman, @jsross119, @gregggonsalves et al! (In addition to the interesting study results, we also discovered that creating Venn diagrams is often easier said than done!)
RT @jsross119: Today in @JournalGIM, we report our @Yale_CRIT study led by @alex_egilman, funded by @JohnArnoldFndtn, estimating how much…
Today in @JournalGIM, we report our @Yale_CRIT study led by @alex_egilman, funded by @JohnArnoldFndtn, estimating how much @CMSGov spent on drugs and biologics that were not recommended for coverage by HTAs in Canada, Australia or England (4/7) https://t.